PACB - パシフィック・バイオサイエンシズ・オブ・カリフォルニア （Pacific Biosciences of California Inc.） パシフィック・バイオサイエンシズ・オブ・カリフォルニアPACBのチャート
PACBの企業情報
| symbol | PACB |
|---|---|
| 会社名 | Pacific Biosciences of California Inc （パシフィック・バイオサイエンシズ・オブ・カリフォルニア） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 パシフィック・バイオサイエンシズ（Pacific Biosciences Inc.）は、科学者が遺伝的に複雑な問題を解決するのに役立つシーケンシングシステムを設計、開発、製造する。同社は遺伝子解析のための統合プラットフォームの開発、製造、販売に従事する。同社の単一分子、リアルタイム（SMRT）技術は、生物学的プロセスの単一分子、リアルタイム検出を可能にする。同社はSMRT細胞、PhospholinkedヌクレオチドおよびPacBio RS IIおよびSequel装置を提供する。同社のSMRT技術は、DNAポリメラーゼによって作動されるDNA複製の自然なプロセスを利用することによってリアルタイムで起こるデオキシリボ核酸（DNA）合成の観察を可能にする。同社のリン酸化されたヌクレオチドは、塩基ではなくヌクレオチドのリン酸鎖に結合した蛍光色素を有する。PacBio RS IIおよびSequel機器には、光学機器、自動液体ハンドリング、タッチスクリーン制御インターフェース、コンピューターハードウェアとソフトウェアが含まれる。 パシフィック・バイオサイエンシズ・オブ・カリフォルニアは、米国のバイオ研究会社。遺伝子解析のための技術を開発、製造、販売する。ナノファブリケ―ション、生化学、分子生物学、表面の化学的性質と光学の発展を組み合わせることで、一回の分子反応で生体分子のリアルタイム分析が可能な単一分子リアルタイム（SMRT）技術プラットフォ―ムを開発した。 Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA. |
| 本社所在地 | 1305 O'Brien Drive Menlo Park CA 94025 USA |
| 代表者氏名 | Michael W. Hunkapiller マイケル・W・ハンカピラー |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-521-8000 |
| 設立年月日 | 36708 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 456人 |
| url | www.pacb.com |
| nasdaq_url | https://www.nasdaq.com/symbol/pacb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -80.57800 |
| 終値（lastsale） | 4.39 |
| 時価総額（marketcap） | 579225182.45 |
| 時価総額 | 時価総額（百万ドル） 639.50650 |
| 売上高 | 売上高（百万ドル） 89.42000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 590.13650 |
| 当期純利益 | 当期純利益（百万ドル） -89.50200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Pacific Biosciences of California revenues decreased 9% to $40.9M. Net loss decreased 5% to $46.7M. Revenues reflect Product revenue decrease of 8% to $34.8M Service and other revenue decrease of 14% to $6.2M. Lower net loss reflects Research and development - Balancing val decrease of 8% to $27.5M (expense) Other Sales general and administrative decrease of 3% to $25.1M (expense). |
PACBのテクニカル分析
PACBのニュース
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue? 2020/06/05 15:31:47 Zacks Investment Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates 2020/05/08 06:57:00 Zacks Investment Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know 2020/04/29 16:34:25 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release 2020/04/24 16:30:34 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec 2020/04/21 11:22:00 Zacks Investment Research
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue? 2020/06/05 15:31:47 Zacks Investment Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates 2020/05/08 06:57:00 Zacks Investment Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know 2020/04/29 16:34:25 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release 2020/04/24 16:30:34 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec 2020/04/21 11:22:00 Zacks Investment Research
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates 2020/05/08 06:57:00 Zacks Investment Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know 2020/04/29 16:34:25 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release 2020/04/24 16:30:34 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.